New immunotherapy trial targets rare cancers in japanese patients
NCT ID NCT07302347
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 22 times
Summary
This study tests the drug pembrolizumab in Japanese children with solid tumors or lymphomas, and in Japanese adults with advanced Merkel cell skin cancer. The main goals are to check the drug's safety, how the body processes it, and whether tumors shrink. About 20 participants will receive the treatment, and researchers will monitor side effects and cancer response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nagoya City University Hospital ( Site 0003)
RECRUITINGNagoya, Aichi-ken, 467-8602, Japan
Contact Phone: •••-•••-••••
-
National Hospital Organization Kyushu Cancer Center ( Site 0001)
RECRUITINGFukuoka, 811-1395, Japan
Contact Phone: •••-•••-••••
-
Sapporo Hokuyu Hospital ( Site 0005)
RECRUITINGSapporo, Hokkaido, 003-0006, Japan
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.